Tabimorelin

CAS: 193079-69-5

Rif. TR-T003500

Informazioni sul prodotto

• Nome: Tabimorelin
• Sinonimi: (R)-alpha-((E)-5-Amino-N,5-dimethyl-2-hexenamido)-N-methyl-N-((R)-alpha-(methylcarbamoyl)phenethyl)-2-naphthalenepropionamide, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexenyl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, N-[(2E)-5-Amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<span class="text-smallcaps">D</smallcap>-alanyl-N,N^α-dimethyl-<smallcap>D</span>-phenylalaninamide, N-[(2E)-5-amino-5-methylhex-2-enoyl]-N-methyl-3-(naphthalen-2-yl)-D-alanyl-N,Nα-dimethyl-D-phenylalaninamide, Nn 703, Nnc 26-0703, Tabimorelin [INN], Unii-L51Cbe03Kf
• CAS: 193079-69-5

Descrizione

Applications NN703 (Tabimorelin) is an orally active growth hormone (GH) secretagogue intended for use as an alternative to daily injections of GH. In vitro studies in human liver microsomes have indicated that NN703 is a mechanism-based inhibitor of CYP3A4.
References Fabre, G., et al.: Biochem. Pharmacol., 37, 4389 (1988), Thummel, K., et al.: Clin. Pharmacol. Ther., 59, 491 (1996), Yu, D., et al.: J. Clin. Pharmacol., 39, 1203 (1999),

• Marchio: TRC

Proprietà chimiche

• Peso molecolare: 528.68
• Formula: C₃₂H₄₀N₄O₃
• Colore/Forma: White to Off-White Solid
• InChI: InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
• InChI key: InChIKey=WURGZWOTGMLDJP-GBDBBNHTSA-N
• SMILES: CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)C(Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N